Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
Current reports
8-K
Design Therapeutics Outlines Progress Across GeneTACâ„¢ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
19 Mar 24
8-K
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
13 Nov 23
8-K
Departure of Directors or Certain Officers
25 Aug 23
8-K
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
14 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
1 Jun 23
8-K
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
9 May 23
8-K
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 23
8-K
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
8 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 22
Registration and prospectus
S-8
Registration of securities for employees
19 Mar 24
S-8
Registration of securities for employees
14 Mar 23
S-3
Shelf registration
27 Apr 22
S-8
Registration of securities for employees
10 Mar 22
S-8
Registration of securities for employees
26 Mar 21
424B4
Prospectus supplement with pricing info
26 Mar 21
8-A12B
Registration of securities on exchange
23 Mar 21
S-1/A
IPO registration (amended)
22 Mar 21
S-1
IPO registration
5 Mar 21
D
$125M in equity, sold $125M, 26 investors
12 Feb 21
Other
EFFECT
Notice of effectiveness
10 May 22
CORRESP
Correspondence with SEC
5 May 22
CORRESP
Correspondence with SEC
2 May 22
UPLOAD
Letter from SEC
29 Apr 22
EFFECT
Notice of effectiveness
26 Mar 21
CERT
Certification of approval for exchange listing
24 Mar 21
SEC STAFF
SEC staff action: Order
24 Mar 21
CORRESP
Correspondence with SEC
23 Mar 21
CORRESP
Correspondence with SEC
23 Mar 21
CORRESP
Correspondence with SEC
22 Mar 21
Ownership
4
John P. Schmid
25 Mar 24
4
Heather A. Berger
25 Mar 24
3
Jae B. Kim
20 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Julie Burgess
5 Jan 24
4
Sean Jeffries
5 Jan 24
4
RODNEY W LAPPE
5 Dec 23
4
Aseem Z. Ansari
5 Dec 23